ArticleVox sanguinis2026
Application and retrospective analysis of the indicator system for non-conforming blood products in Beijing.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectivesSystematic evaluations of blood discard patterns remain limited. We analysed decade-long discard trends at a representative blood establishment to identify quality improvement opportunities. MATERIALS AND
methodsDiscard data for blood products collected from 1 January 2015 to 31 December 2024 were obtained from the Beijing Red Cross Blood Center, classifying discards as test-related or non-test-related. Pareto charts identified major drivers of discard, and
resultsThe overall discard rate averaged 3.050%, peaking at 4.398% in 2021 before declining to 2.410% in 2024 (Z = -6.111, p < 0.0001). Non-test-related discards increased significantly from 0.720% in 2015 to 2.636% in 2021 (mean: 1.118%/year; Z = 26.478, p < 0.0001), before recovering to below pre-pandemic levels by 2024. Test-related discards decreased significantly from 2.254% in 2015 to 1.663% in 2020 and continued to decrease through 2024 (mean: 1.921%/year; Z = -27.454, p < 0.0001). Major discard drivers included lipaemic blood retest (LBR) in plasma, crossmatch incompatibility (CI) in red blood cell (RBC) products and alanine aminotransferase (ALT) retest failure. Plasma bag leakage (BL), platelet visual inspection abnormality (VIA), expired units and Treponema pallidum antibody (TP-Ab) and hepatitis C virus antibody (HCV-Ab) test-related discards, all showed significant downward trends (p < 0.001).
conclusionDivergent trends between test-related discards (declining from 2.254% to 1.663%) and non-test-related discards (increasing from 0.720% to 2.636%) indicate that although laboratory screening has improved substantially, greater attention is needed to optimize collection, processing and handling practices.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.